What DEA TOX's Q2 2023 Analysis Tells Us About The Current State of Synthetic Drug Abuse
The Drug Enforcement Administration’s Toxicology Testing Program (DEA TOX), initiated in May 2019, continues to play a vital role in addressing the synthetic drug issue in the U.S. This collaborative effort, joining forces with local health departments, law enforcement, and medical facilities, aims at identifying new psychoactive substances (NPS) circulating within the country.
In its recent analysis covering the second quarter of 2023, from April 1 to June 30, DEA TOX has provided valuable insights into the current drug trends by examining biological samples from individuals who overdosed on synthetic drugs.
Proliferation of New Psychoactive Substances (NPS)
The endeavor led to the identification of 110 NPS detections from 192 biological samples across 168 cases. The synthetic opioids and benzodiazepines emerged as the predominant classes within the NPS category. This data is instrumental in mapping the evolution of synthetic drugs and their detrimental impact on public health.
Traditional Illicit Drugs (TID) - A Persistent Threat
The menace of traditional illicit drugs (TID) remains unabated with 409 detections. Methamphetamine continues to be a significant contributor to the TID category, underscoring the enduring challenge posed by these substances.
Prescription and OTC Drugs - A Closer Look
In a telling revelation, the analysis confirmed 436 detections of prescription or over-the-counter (OTC) drugs. This underscores the necessity for a more stringent regulation and monitoring framework to curb misuse.
Precursors/Additives/Impurities (P/A/I) - The Hidden Dangers
The study also unveiled 133 detections of Precursors, Additives, and Impurities (P/A/I), highlighting the covert risks associated with drug consumption. Adulterants like quinine and xylazine were notably prevalent, hinting at the layered dangers inherent in drug misuse.
Drug Products Analysis
Furthering the comprehensiveness of the study, two drug product samples were scrutinized, unveiling the presence of fentanyl and gabapentin. This facet of the analysis augments the understanding of the composition and potential hazards of drug products in circulation.
The insights furnished by the DEA TOX report are instrumental in not only comprehending the present drug landscape but also in devising informed strategies to combat the synthetic drug crisis. The comprehensive report is available here, providing a deeper dive into the findings and their implications.
